<DOC>
	<DOCNO>NCT02930889</DOCNO>
	<brief_summary>This investigator-initiated evaluation safety efficacy treat benign prostatic hyperplasia ( BPH ) prostatic artery embolization .</brief_summary>
	<brief_title>Prostate Artery Embolization ( PAE ) Lower Urinary Tract Symptoms ( LUTS ) Due Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description>This investigator-initiated evaluation safety efficacy treat benign prostatic hyperplasia ( BPH ) prostatic artery embolization .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Male , 45 year old Diagnosis Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia refractory medical therapy least 6 month . IPSS score initial evaluation great 12 , uroflowmetry ( Qmax ) &lt; 15mL/s ( milliliter per second ) . All prostate volume &gt; 40gm PSA meet one follow criterion : Baseline PSA ≤ 2.5ng/mL , Baseline PSA &gt; 2.5 ng/mL ≤ 10 ng/mL AND free PSA ≥ 25 % total PSA ( biopsy require ) ; Baseline PSA &gt; 2.5 ng/mL ≤ 10 ng/mL AND free PSA &lt; 25 % total PSA AND negative prostate biopsy result ( minimum 12 core biopsy ) within 12 month ; Baseline PSA &gt; 10 ng/mL AND negative prostate biopsy result ( minimum 12 core biopsy ) within 12 month ; Negative prostate biopsy ( minimum 12 core within 12 month ) abnormal digital rectal examination . Patients active urinary tract infection recurrent urinary tract infection ( &gt; 2/year ) , prostatitis , interstitial cystitis . Cases biopsy proven prostate , bladder , urethral cancer . Patients longterm narcotic analgesia , androgen therapy , GNRH ( gonadotropinreleasing hormone ) analogue therapy unwilling stop therapy 2 month prior study . Use anithistamines , anticonvulsant , antispasmodic within one week treatment unless treat drug ( dosage ) least 6 month associate stable voiding pattern . Patients classify New York Heart Association Class III ( Moderate ) , high , cardiac arrhythmia , uncontrolled diabetes , know immunosuppressed . Hypersensitivity reaction contrast material manageable prophylaxis . Patients glomerular filtration rate less 40 already dialysis Prostate volume &lt; 40 mL Patients bilateral internal iliac arterial occlusion Patients cause bladder obstruction due BPH ( eg urethral stricture , bladder neck contraction , etc ) Patients neurogenic bladder atonia Prior prostatectomy Cystolithiasis within last 3 month Patients interested future fertility Patients life expectancy le 1 year Patients embolization possible distal collateral vessel feed nonprostatic tissue Patients major neurologic illness could symptoms may similar confuse BPH ( eg Parkinson 's disease , multiple sclerosis , ShyDrager syndrome , spinal cord injury , etc. ) . Patients urethral stent Patients undergone prior rectal surgery hemorrhoidectomy pelvic irradiation . Patients start change dosage alpha blocker 5alpha reductase inhibitor month prior PAE</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Therapeutic Embolization</keyword>
	<keyword>Prostatic Artery Embolization</keyword>
</DOC>